Novartis's Cosentyx Climbs Despite Competitors And COVID-19
First Billion Dollar Quarter For Anti-IL-17 Blockbuster
CEO Vas Narasimhan told Scrip how impressed he was by the resilience of the brand and while Cosentyx is holding its market share in dermatology, its rheumatology sales are continuing to fly high.
